Affimed GmbH

Industry · 9 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma	Phase 2	2023-10-10
Terminated	First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia	Phase 1	2023-03-21
Terminated	Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers Advanced Solid Tumor	Phase 1 / Phase 2	2021-11-19
Terminated	Study to Assess AFM24 in Advanced Solid Cancers Advanced Solid Tumor	Phase 1 / Phase 2	2020-04-07
Completed	Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungo Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides	Phase 2	2019-11-13
Terminated	Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL Leukemia, B-Cell	Phase 1	2016-10-01
Completed	Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Hodgkin Lymphoma	Phase 1	2016-05-01
Terminated	Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1	2014-04-01
Completed	A Study to Assess AFM13 in Patients With Hodgkin Lymphoma Hodgkin Lymphoma	Phase 1	2010-10-01